ASKC202

Main purpose To evaluate the safety and tolerability of single and multiple administrations of ASKC202 tablets in patients with advanced solid tumors, and to determine the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of ASKC202 tablets. To evaluate the safety and tolerability of ASKC202 tablets combined with ASK120067 tablets in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC), and to determine the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of ASKC202 tablets combined with ASK120067 tablets. Secondary purpose To evaluate the pharmacokinetic characteristics of ASKC202 tablets in patients with advanced solid tumors; to evaluate the preliminary anti-tumor efficacy of ASKC202 tablets in patients with advanced solid tumors, and to provide a basis for determining the dosing regimen for subsequent clinical studies. To evaluate the pharmacokinetic characteristics of ASKC202 tablets combined with ASK120067 tablets in patients with locally advanced or metastatic NSCLC; to evaluate the preliminary anti-tumor efficacy of ASKC202 tablets combined with ASK120067 tablets in patients with locally advanced or metastatic NSCLC, and to provide a basis for determining the dosing regimen for subsequent clinical studies.